Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:22:57 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:CYDY - CYTODYN INC - https://www.cytodyn.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYDY - Qnot subscribed0.249+0.0031.21,424.43432230.25  0.255  0.2430.4945  0.191115:59:57Jan 2715 min RT 2¢

Recent Trades - Last 10 of 223
Time ETExPriceChangeVolume
15:59:57Q0.24780.0018100
15:59:57Q0.2490.003100
15:58:38Q0.2457-0.0003100
15:58:23Q0.24640.00045,000
15:53:43Q0.24970.00374,000
15:53:43Q0.2486950.0026954,000
15:53:32Q0.246350.000351,000
15:49:37Q0.247140.001141,000
15:49:37Q0.24980.00381,000
15:49:13Q0.246450.00045558

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-27 08:30U:CYDYNews ReleaseCytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
2025-12-16 08:30U:CYDYNews ReleaseDecember 2025 Letter to Shareholders
2025-12-08 08:30U:CYDYNews ReleaseCytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
2025-12-01 08:30U:CYDYNews ReleaseCytoDyn Announces Resolution of Class Action Lawsuit
2025-11-24 08:30U:CYDYNews ReleaseCytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
2025-11-03 08:30U:CYDYNews ReleaseCytoDyn Secures $30 Million Commitment from Yorkville Advisors
2025-10-09 08:30U:CYDYNews ReleaseCytoDyn to Present at the LD Micro Main Event XIX Investor Conference
2025-09-30 08:31U:CYDYNews ReleaseSeptember 2025 Letter to Shareholders
2025-09-25 08:30U:CYDYNews ReleaseCytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
2025-09-16 08:30U:CYDYNews ReleaseCytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
2025-09-04 08:30U:CYDYNews ReleaseCytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
2025-08-28 08:30U:CYDYNews ReleaseCytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference
2025-07-01 08:30U:CYDYNews ReleaseCytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
2025-06-24 08:30U:CYDYNews ReleaseCytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
2025-05-15 08:30U:CYDYNews ReleaseCytoDyn Releases ESMO Breast Cancer Meeting Poster
2025-05-13 08:30U:CYDYNews ReleaseCytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
2025-05-06 08:30U:CYDYNews ReleaseCytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
2025-04-29 08:30U:CYDYNews ReleaseCytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
2025-03-18 08:30U:CYDYNews ReleaseMarch 2025 Letter to Shareholders
2025-02-24 08:30U:CYDYNews ReleaseCytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab